Top 5 Reasons Why You Should Attend Veeva R&D Summit, Europe

pharmafile | March 15, 2018 | News story | Medical Communications biotech, drugs, pharma, pharmaceutical, veeva 

Veeva R&D Summit, Europe is an annual gathering of pharma, biotech and medical devices professionals in clinical, regulatory, quality, and IT.

Now in its fourth year, the event will be hosted at the Fairmont Rey Juan Carlos I on the 12-14 June in Barcelona, and more than 350 delegates are expected to attend.

The agenda features dedicated tracks focused on driving end-to-end business processes across product development.

If you haven’t attended Veeva R&D Summit before, here are the top 5 reasons you shouldn’t miss this conference:

  • Learn from industry leaders. Find out how your peers tackle challenges, such as ensuring inspection-readiness, managing regulatory events, and incorporating partners into key quality processes.
  • Meet the European R&D ecosystem. Wander the partner pavilion to hear from companies such as Accenture, NNIT, and Valiance.
  • See what’s coming next. Discover the latest innovations to improve operations across your development process.
  • Your questions answered by the experts. Meet product management, and experience Veeva Vault applications with hands-on demos, and learn from other users.
  • Have fun. Catch up with your colleagues during the networking opportunities and make new connections.

Find out why previous attendees think Summit is worth attending in this infographic.

The conference is complimentary for qualified attendees. Please reserve your spot today

Rik van Mol

VP, Veeva Vault R&D, Europe

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content